Navigation Links
ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0

FREMONT, Calif., June 26 /PRNewswire/ -- ValGenesis, Inc., a leading provider of Enterprise Validation Management software solutions, announced the worldwide availability of ValGenesis 2.0, the latest version of its breakthrough Web-based, multi-site, scalable validation life cycle management and automation product.

Life science companies implementing the ValGenesis software suite can efficiently manage the entire validation life cycle and move securely from manual, paper-based validation processes to a 100 percent paperless, fully electronic validation process. ValGenesis enforces consistency and enhances compliance in the corporate validation process. Users see a holistic view of a company's validation status and are able to identify bottlenecks, reducing validation cycle time and cost by 40 to 50 percent.

An out-of-the-box solution, with template-driven rapid implementation methodology requiring less overall implementation and validation time, this allows ValGenesis clients' Information Technology and Validation personnel to easily manage other projects in parallel. Among the enhancements in ValGenesis 2.0 are improved requirements management, expanded traceability matrix capability, risk assessment, offline validation execution, workflow design and collaboration through the robust library module.

ValGenesis 2.0 features the ability to implement a single validation system for all corporate/site validation requirements. A centralized deployment provides easier maintenance. By providing 360-degree visibility to the validation process, communication among all cross-functional users is significantly enhanced, while internal and external audit preparation time is reduced by 90 percent. End-users can easily personalize the web-based interface to their needs and interest.

"ValGenesis 2.0 includes substantial technological advancements, enhances the team-based review and can be hosted at a single location and deployed globally in order to address our customers' increasing need for collaboration in today's stringently regulated marketplace," said Siva Samy, PhD, ValGenesis Chief Product Strategist. "We have incorporated several new features and enhancements based on recommendations from our customers which allow our new customers to fully address their core validation requirements and expedite the validation process while remaining fully compliant with industry regulations." He added, "This version introduces the first phase of our new integration initiative. We've partnered with leading companies in the content management and ERP sectors to provide fully integrated solutions." Samy said, "We are particularly excited about the potential for significant savings to our clients using this version's global validation capabilities in which reviewers, approvers and engineers (developers and testers) can share and review information from different locations simultaneously."

About ValGenesis

ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies. ValGenesis is the first Enterprise application to automate the validation life cycle of GxP systems and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA) awarded ValGenesis the prestigious New Innovative Technology award.

For more information, visit ValGenesis's web site at

Press Contact:

Mike Beaudro

Marketing Manager

Ph: 510 445 0505

This release was issued through eReleases(TM). For more information, visit

SOURCE ValGenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):